UNSPSC 51144120: Fenproporex

This classification denotes an anorexiant with the molecular formula C12H16N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W0194S5FOA, chemically known as propionitrile, 3-((alpha-methylphenethyl)amino)-, (+-)- but more generally known as fenproporex, which bears US NIH Compound Identifier 61810. European Medicines Agency schedules Fenproporex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07592MIG. The term FENPROPOREX is an International Non-Proprietary Name.

UNSPSC 51144120 Fenproporex, a Commodity code, nominally names a single pharmaceutical product, but recent state and local solicitation activity shows little direct procurement of fenproporex itself. Instead, state and local governments are buying broader pharmaceutical and health-related products through this code tag: naloxone and drug deactivation systems for public health response, generic multi-source pharmaceuticals and over-the-counter products for statewide distribution networks, and exploratory direct-to-manufacturer prescription programs. The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The scope reflects community health initiatives, pharmacy benefit programs, and controlled substance management rather than fenproporex specifically.

Recent activity centers on Florida, Texas, and Minnesota-Oregon. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring fixed-fee pricing and standard insurance and compliance certifications. The Texas HHS Commission issued a Request for Information on April 3, 2026 regarding direct-to-manufacturer prescription programs, an exploratory procurement to inform future formal solicitations. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP due March 26, 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with evaluation weighted 75 percent on price competitiveness and 10 percent on fixed pricing, requiring cGMP and Drug Supply Chain Security Act compliance and commercial general liability insurance of $5,000,000 per occurrence. The code shows fragmented activity across health authorities with no clear concentration or repeat-buyer pattern in the recent opportunities block.